Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol
Abstract Background Non-alcoholic fatty liver disease (NAFLD) affects 20–30% of the general adult population. NAFLD patients with type 2 diabetes mellitus (T2DM) are at an increased risk of advanced fibrosis, which puts them at risk of cardiovascular complications, hepatocellular carcinoma, or liver...
Main Authors: | Patrik Nasr, Fredrik Iredahl, Nils Dahlström, Karin Rådholm, Pontus Henriksson, Gunnar Cedersund, Olof Dahlqvist Leinhard, Tino Ebbers, Joakim Alfredsson, Carl-Johan Carlhäll, Peter Lundberg, Stergios Kechagias, Mattias Ekstedt |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-021-01763-z |
Similar Items
-
SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
by: Dimitrios Patoulias
Published: (2018-04-01) -
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD
by: Jennifer Linge, et al.
Published: (2021-02-01) -
Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance?
by: Mireia Alemany-Pagès, et al.
Published: (2020-07-01) -
Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort.
by: Mikael F Forsgren, et al.
Published: (2019-06-01) -
Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases
by: Tatsuya Kondo, et al.
Published: (2021-05-01)